Impediments to growth are melting away while new opportunities begin to rise.Eli Lilly (LLY -1.01%) and Novo Nordisk (NVO -1.58%) give new meaning to the word "unstoppable" in the context of pharma stocks. Whereas the total return of Lilly's shares soared by 245% over the last three years, Novo Nordisk's rose by 165%, meaning that both easily beat the broader market's growth of just 25%.There's little indication that either company is about to slow down significantly, even in the face of a couple of headwin ...